Author: Daniel Eisenman, PhD, RBP, SM(NRCM), CBSP Publication: Clinical Researcher

Daniel Eisenman, PhD, RBP, SM(NRCM), CBSP, Director of Biosafety Services, contributed to the article Safety Precautions for Laboratory Research with SARS-CoV-2 Positive Specimens and COVID-19 Subjects in Clinical Researcher.

The global pandemic caused by the coronavirus (SARS-CoV-2) and the disease it causes (COVID-19) have brought biosafety to the forefront of most everyone’s minds. Things like hand hygiene, personal protective equipment (PPE), and respiratory protection are no longer niche topics.

The research community is seeing a surge of interest in the requisite safety practices for research involving specimens from SARS-CoV-2 positive individuals and COVID-19 subjects. The Centers for Disease Control and Prevention (CDC), the Occupational Safety and Health Administration (OSHA), and the American Biological Safety Association International (ABSA International) have issued guidelines for the implementation of well-established safety practices for such research. Biosafety practices must be customized to the proposed research as well as the existing facility and local regulatory requirements. Proper biosafety measures are critical to conducting safe, high quality research during this uncertain time.

Back to Resources